Epoch Investment Partners Inc. Sells 74,956 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Epoch Investment Partners Inc. decreased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 8.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 778,311 shares of the biopharmaceutical company’s stock after selling 74,956 shares during the quarter. Epoch Investment Partners Inc.’s holdings in Halozyme Therapeutics were worth $37,211,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Stifel Financial Corp increased its holdings in shares of Halozyme Therapeutics by 126.3% during the third quarter. Stifel Financial Corp now owns 17,121 shares of the biopharmaceutical company’s stock worth $980,000 after buying an additional 9,555 shares in the last quarter. MML Investors Services LLC grew its holdings in Halozyme Therapeutics by 80.7% during the 3rd quarter. MML Investors Services LLC now owns 9,779 shares of the biopharmaceutical company’s stock worth $560,000 after acquiring an additional 4,366 shares during the last quarter. M&T Bank Corp grew its stake in shares of Halozyme Therapeutics by 0.5% in the third quarter. M&T Bank Corp now owns 111,239 shares of the biopharmaceutical company’s stock worth $6,367,000 after purchasing an additional 561 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Halozyme Therapeutics in the third quarter valued at about $434,000. Finally, World Investment Advisors LLC acquired a new stake in Halozyme Therapeutics during the 3rd quarter valued at approximately $3,293,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Activity

In related news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the sale, the director now directly owns 38,611 shares in the company, valued at approximately $2,173,799.30. This trade represents a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the transaction, the senior vice president now owns 185,453 shares of the company’s stock, valued at $10,765,546.65. This trade represents a 5.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,200 shares of company stock worth $1,286,568 over the last quarter. Insiders own 2.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on HALO shares. Piper Sandler boosted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Benchmark reissued a “buy” rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company cut their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Finally, HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $62.78.

Halozyme Therapeutics Trading Down 0.1 %

HALO opened at $58.79 on Friday. The firm has a market capitalization of $7.26 billion, a PE ratio of 17.14, a P/E/G ratio of 0.42 and a beta of 1.32. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.97 and a fifty-two week high of $66.00. The company’s 50-day moving average is $60.45 and its 200 day moving average is $55.02.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. The company had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. As a group, research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.